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Dysferlinopathy is a muscular dystrophy with a highly variable functional disease
progression in which the relationship of function to some patient reported outcome
measures (PROMs) has not been previously reported. This analysis aims to identify
the suitability of PROMs and their association with motor performance.Two-hundred
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and four patients with dysferlinopathy were identified in the Jain Foundation’s Clinical
Outcome Study in Dysferlinopathy from 14 sites in 8 countries. All patients completed
the following PROMs: Individualized Neuromuscular Quality of Life Questionnaire (INQoL),
International Physical Activity Questionnaire (IPAQ), and activity limitations for patients
with upper and/or lower limb impairments (ACTIVLIMs). In addition, nonambulant patients
completed the Egen Klassifikation Scale (EK). Assessments were conducted annually at
baseline, years 1, 2, 3, and 4. Data were also collected on the North Star Assessment for
Limb Girdle Type Muscular Dystrophies (NSAD) and Performance of Upper Limb (PUL) at
these time points from year 2. Data were analyzed using descriptive statistics and Rasch
analysis was conducted on ACTIVLIM, EK, INQoL. For associations, graphs (NSAD
with ACTIVLIM, IPAQ and INQoL and EK with PUL) were generated from generalized
estimating equations (GEE). The ACTIVLIM appeared robust psychometrically and was
strongly associated with the NSAD total score (Pseudo R2 0.68). The INQoL performed
less well and was poorly associated with the NSAD total score (Pseudo R2 0.18).
EK scores were strongly associated with PUL (Pseudo R2 0.69). IPAQ was poorly
associated with NSAD scores (Pseudo R2 0.09). This study showed that several of the
chosen PROMs demonstrated change over time and a good association with functional
outcomes. An alternative quality of life measure and method of collecting data on physical
activity may need to be selected for assessing dysferlinopathy.
Keywords: limb girdle muscular dystrophy, dysferlinopathy, PROMs, quality of life, clinical outcome assessments

INTRODUCTION

into examining PROMs in this group over time and has
shown the ACTIVLIM to detect change even in a period of
6 months (14), limited work has been done on the other
patient measures.
The Jain Clinical Outcomes Study (COS) for dysferlinopathy
was established to address the lack of comprehensive natural
history data for dysferlinopathy, particularly around PROMs,
and to identify if these were associated with functional changes
related to disease progression. The aim of the present paper
is to evaluate the suitability and change of selected PROMs
from baseline up to a maximum of 4 years and to examine
the association between these measures and the North Star
Assessment for Limb Girdle Type Muscular Dystrophies (NSAD)
(15) and the Performance of Upper Limb (PUL) (16), both as
measures of motor performance.

Dysferlinopathy is a rare, autosomal recessive muscular
dystrophy caused by mutations in the DYSF gene, which encodes
the skeletal muscle protein dysferlin (1, 2). The most common
clinical diagnoses associated with dysferlinopathy are limb
girdle muscular dystrophy type 2B (LGMDR2 dysferlin related)
and a distal posterior myopathy known as Miyoshi myopathy
1 MM1 (3, 4). Though onset typically occurs during young
adulthood, clinical presentation is inconsistent, with a wide
range of ages of onset, patterns of muscle weakness, and severity,
despite the fact that most patients share a loss of expression
of the dysferlin protein (1, 5–7). Likewise, disease progression
is variable; loss of ambulation occurs 5 to 35 years after onset
of muscle weakness, while a small number of patients remain
only mildly affected for decades (8, 9). A number of factors
that may influence the clinical phenotype and progression of
dysferlinopathy have been proposed, including exercise and the
specific mutation (5, 10, 11), though no clear pattern of decline
or genotype–phenotype correlation has been established.
Of key importance to developing appropriately designed
clinical trials in this group and to provide support and
appropriate management for patients is understanding the
natural history of the disease over time, particularly its
impact on function, activities of daily living and ultimately
quality of life. These are generally described as Patient
Reported Outcome Measures (PROMs) or Patient Centered
Outcome Measures (PCOMs). They are deemed a necessity
for evaluating disease progression and the efficacy and clinical
meaningfulness of therapeutic interventions by experts (12)
and regulatory authorities (13). Although some work has gone
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METHODS
Clinical Outcomes Study is a multicenter, international study
of patients with a confirmed diagnosis of dysferlinopathy.
Detailed study methods have been published previously (8, 14).
In order to be included in COS, patients were required to
have two pathogenic mutations in DYSF, or one pathogenic
mutation plus either absent dysferlin expression on immunoblot
or <20% dysferlin monocyte expression. Each participating site
received local ethics approval and written informed consent
was obtained for all patients. The study was registered at
ClinicalTrials.gov (NCT01676077).
The present study includes data from 204 patients at 14 sites;
one original site was excluded from the present analysis due to

2

March 2022 | Volume 13 | Article 828525

Number of pairs of
dependent items

2

33

0

Number of items
with good fit*

16/18 (89%) 16a
/ 16b

20/39 (51%) 26a
/ 24b

8/10 (80%) 8a / 9b

Acceptable

Acceptable?

Dependency

Self-reported race (if allowed by the participating country) and
patient gender were recorded at baseline. Age at each study
visit was approximated using the visit date and patient’s year of
birth. Clinical diagnosis of LGMDR2, MM1, or other (consisting
primarily of hyperCKemia) was recorded based on the diagnostic
label given by the diagnosing clinician, as reported by patients.
Ambulatory status was defined at the point of assessment by the
ability to complete a 10-m walk distance independently (gait aids
permissible) as part of the physiotherapy assessment.

A wide range of measures were included in the study,
including measures of function and muscle strength, in order
to establish their usefulness in assessing disease progression
over time. For this study, we examined all patients who
completed the following PROMs as appropriate: ACTIVLIM,
International Physical Activity Questionnaire (IPAQ), and the
Individualized Neuromuscular Quality of Life Questionnaire
(INQoL). Nonambulant patients also completed the Egen
Klassifikation (EK) scale. Assessments were conducted annually
at baseline, years 1, 2, and 3 for some at year 4. Data were also
collected on motor performance at these time points (8).
The ACTIVLIM is a validated patient reported outcome
measure of functional ability based on perceived difficulty in
performing specific activities of daily living (17). Total scores
range from 0 to 36, with higher scores suggesting better function.
International Physical Activity Questionnaire assesses a
person’s physical activity levels using a set of seven questions
and describes that activity in terms of time spent and level of
intensity (18). There are two forms of output from scoring the
IPAQ. Results can be reported in categories (low activity levels,
moderate activity levels or high activity levels) or as a continuous
variable (Metabolic Equivalent Task (MET) minutes a week).
Individualized Neuromuscular Quality of Life Questionnaire
is a quality of life measure that aims to capture the impact
of key muscle disease symptoms and the impact on activities,
independence, relationships, and body image (19).
The EK scale is a patient’s assessment of their “own
functioning” related to daily tasks and was designed
for nonambulant pediatric and adult patients with
Duchenne muscular dystrophy (DMD) and spinal
muscular atrophy (20, 21).
The NSAD is a Rasch-developed clinician reported outcome
(ClinRO) of motor performance suitable for ambulant
and nonambulant adults and children, validated in this
dysferlinopathy (LGMDR2) cohort, and has been shown to be
very sensitive to change over 1 year (15).
The PUL scale was designed specifically to measure upper
limb motor performance across the spectrum of severity in
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* Fit:

defined as fit residual inside the recommended range (–2.50 to +2.50) a and nonsignificant v2 probability (p<0.001) b .

3/10
(30%)
0.76
0.00 (120)
−0.22 (1.737)
250 (5) = 245
EK

−0.423 (0.576)

15/39
(38%)
0.95
0.00 (351)
0.65 (3.039)
660 (2) = 658
INQoL

−0.09 (1.703)

18/18 (100 %)
0.95
0.00 (162)
−0.37 (0.883)
−0.05 (1.963)
787 (66) = 721

Mean (SD)
N (no. of extremes)
available

ACTIVLIM

Ordered
thresholds
Psi with extremes

Item fit

Mean (SD)

Overall item-trait
interaction chi 2
value (DF)

Reliability
Person fit

Demographic and Clinical Measures

Outcome Measures

Rasch summary

TABLE 1 | Summary Rasch results for ACTIVLIM, INQoL, and EK scales.

Not acceptable

Test of
unidimensionality

the level of missing data over the 4-year period. Participants were
evaluated on PROMs up to five times over the course of the
study: baseline (visit 1), 12 (V2), 24 (V3), 36 (V4), and for some
at 48 (V5) months. Visits took place between November 2012
and March 2018. Follow-up rate was high with 163 participants
(87.2%) completing all five study visits across the 14 sites.

Not acceptable

PROMs in Dysferlinopathy

Item fit
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FIGURE 1 | Threshold map showing all items ordered in the ACTIVLIM Scale in order of difficulty. Threshold map for items in ranked order of difficulty according to
Rasch analysis. “Impossible” labeled 1; “With difficulty” labeled 2; “Easy” labeled 3. There were no reversed thresholds. This is why the figure legend suggested that
disordered thresholds will be labeled with a double asterisk but none are disordered. The implication of this is that as a person’s functional ability increases (move left
to right) they would be more likely to score higher in a consistent and hierarchical way for all questions.

FIGURE 2 | Person–item location distribution for the EK scale. Targeting of the patient sample (top) to the EK items (bottom). The figure shows the adequate targeting
between the distribution of person measurements (upper histogram) and the distribution of item locations (lower histogram). There are no ceiling/floor effects indicated
by the range of the person measurements (upper histogram “blocks”) falling within the item locations (lower histogram “blocks”).
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FIGURE 3 | Association between Total NSAD score and ACTIVLIM. NSAD, North Star Assessment for Limb Girdle Type Muscular Dystrophies; ACTIVLIM, Measure of
Activity Limitations in Daily Living.

targeting of the scales by plotting item location for them
separately and comparing individual person–item threshold
distribution maps for any significant floor or ceiling effects
or gaps in the continuum of measurements in the two scales;
(5) dependency, which determines if the response on one
item influences the response on another item (this is assessed
by examining the residual correlations); and finally (6) a ttest of unidimensionality. Details on these methods can be
found elsewhere (26).

pediatric and adult DMD, is also a Rasch-built ClinRO, and
has been shown to be valid and sensitive to change in DMD
over time (22, 23).

Rasch Analysis
For rating scales (ACTIVLIM, INQoL, EK), Rasch analysis
(RUMM2030 software) was conducted. Essentially, a Rasch
analysis examines the extent to which the observed data
(in this instance, patients’ ratings on scale items) “fit” with
predictions of those ratings from the Rasch model (which defines
how a set of items should perform to generate discriminant,
reliable, and valid measurements) (24). Data were entered
into Rasch Unidimensional Measurement Model RUMM2030
(standard version; RUMM Laboratory Pty Ltd, Perth, Australia).
Analyses assessed (1) item fit to the underlying construct of
the questionnaire (all items should lie within a fit residual
range of SD 2.5); (2) whether the scoring within each item
reflected perceived progression (ordering of thresholds); (3)
reliability, as indicated by a Person Separation Index of more
than 0.8, which is equivalent to Cronbach’s alpha (25); (4)

Frontiers in Neurology | www.frontiersin.org

Statistical Analysis
Data were analyzed using descriptive statistics for each visit
and the entire study. For associations, graphs (NSAD with
ACTIVLM, IPAQ and INQoL and EK with PUL) were
generated from generalized estimating equations (GEE) based
on preliminary examination of cubic spline graphs. Spearman
correlation coefficients are presented for reference. Pseudo R2
for fixed effects were estimated from generalized linear mixed
models using techniques described by Jaeger et al. (27).
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FIGURE 4 | Association between total NSAD score and IPAQ. NSAD, North Star Assessment for Limb Girdle Type Muscular Dystrophies; IPAQ, International Physical
Activity Questionnaire.

RESULTS

not including the treatment section, as only 23% of the cohort
answered the questions relating to treatment and their responses
included a wide variety of management techniques which were
not comparable. However, a sub-total score was calculated on all
questions unrelated to treatment.
For EK, a total of 208 questionnaires were reviewed over 4
time points (245 for Rasch over 5 time points) in nonambulant
individuals. The median score was 7 (range 1–21), out of a
maximum of 30, with higher scores indicating being less able.
See Appendix A for a summary of PROM data over the
different time points.

Of the cohort of 204 patients, 97 were men and 107 were women.
Median age at baseline assessment was 36 years of age, range of
8–86. At baseline 76% of the study cohort were ambulant.

Descriptive Results
For ACTIVLIM, a total of 733 questionnaires were reviewed over
4 time points (787 for Rasch over 5 time points); 2% showed
scores under 16 and were excluded from Rasch analysis as they
would have answered a different subset of four items. Median
score was 23 (range 0–36).
For IPAQ, a total of 748 questionnaires were reviewed over
4 time points. Eighty-two percent of patients undertook no
vigorous exercise, 59% undertook no moderate exercise, 40%
did no walking exercise for more than 10 min. The mean time
spent sitting per day was 9.4 h (SD 4.7). Twenty-four percent
were nonambulant.
For INQoL, a total of 660 questionnaires were reviewed over
4 time points. Total scores were calculated on a subset of items

Frontiers in Neurology | www.frontiersin.org

Rasch Analysis
The results of the Rasch analysis for the three rating scales
are presented in Table 1. The data included the year 4 data
that were available for these Rasch analyses. The ACTIVLIM
presented as a scale with good fit to the population with all
items showing ordered thresholds (Figure 1) and 89% of items
showing good fit with minimal dependency and an acceptable
level of unidimensionality.
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FIGURE 5 | Association between total NSAD score and INQoL. NSAD, North Star Assessment for Limb Girdle Type Muscular Dystrophies; INQoL, Individualized
Neuromuscular Quality of Life Questionnaire.

patient-centered outcomes with measures of motor performance
can add clinical meaning to motor measures which in turn could
be valuable within the clinical trial setting. For example, do
changes in arm function measured on the PUL reflect changes
in how easy or hard it is for an individual to wash and dress their
upper body?
At the beginning of COS, the choice of PROMs needed careful
consideration as no gold standard existed for this population.
The ACTIVLIM and INQoL were chosen as they had been built
using modern psychometric methods and had demonstrated
some evidence of suitability in neuromuscular disease (17, 19).
The IPAQ was used because activity had not been studied in
the group and was felt to be a significant factor, and the EK
was selected to capture “own functioning” in the nonambulant
patient population. The ACTIVLIM performed particularly well
psychometrically in this population with adequate targeting,
ordered thresholds, and most items fitting the construct well. The
EK scale contained several clinically relevant items for this group;
however, some items around respiratory insufficiency appeared
to be not relevant for the nonambulant dysferlinopathy patients.

The INQoL performed less well with poor ordering of
thresholds (38%), unacceptable unidimensionality and limited
item fit to the construct of Health Related Quality of Life
(HRQoL), although adequate targeting was apparent with only
a small floor effect. For the EK, ordering of the thresholds was
low but items showed good fit and targeting (Figure 2) and
unidimensionality was acceptable.
The ACTIVLIM was strongly associated with the NSAD total
score (Pseudo R2 0.68), whereas the INQoL was poorly associated
with the NSAD total score (Pseudo R2 0.18), as was the IPAQ
Total METS (Pseudo R2 0.09). For the nonambulant population,
the EK was strongly associated with the PUL total score (Pseudo
R2 0.69) (Figures 3–6).

DISCUSSION
Findings from the present study in dysferlinopathy provide
useful information on the suitability (i.e., do the scales work
as measurement tools?) of four PROMs to capture the patient’s
opinion. In addition, understanding the relationship between

Frontiers in Neurology | www.frontiersin.org
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FIGURE 6 | Association between total PUL score and EK scale. EK, Egen Klassification questionnaire; PUL, Performance of Upper Limb Scale.

However, the association of arm function with scores on the EK
has been demonstrated in DMD (28) and it may be that a subset
of the items could be identified to capture function in the weaker
population. The association of EK to arm function, although
strong, is not linear, which may indicate that different domains
are captured by the individual scales. The IPAQ also did not
correlate with functional status as measured by NSAD; however,
it is not designed specifically to capture activity and exercise
in the nonambulant population and meta-analysis has shown
that it is perhaps not capturing activity satisfactorily (18). The
INQoL performed less well psychometrically, with poor ordering
of thresholds and limited item fit to the construct of HRQoL,
although adequate targeting was apparent with only a small floor
effect. It was not associated with functional status, although
it is understood that quality of life is not solely dependent
on functional abilities (29) and many individuals with motor
impairment report high satisfaction with their lives.
This study had some limitations. Not all the measures selected
were suitable for nonambulant individuals, which made up a

Frontiers in Neurology | www.frontiersin.org

quarter of our cohort, which, for example, could result in a
limited understanding of activity levels in this group. It may have
been beneficial to review and adapt some of the PROMs prior
to testing in such a large cohort. This could have identified any
unnecessary or unsuitable questions: for example, the swallowing
and eating items within the EK scale. However, evidence of how
scales work in their original format removes the concern that
changes made to it prior to full evaluation were unjustified. We
also acknowledge that although chronic pain is recognized as
being a significant issue for LGMD (30), we did not specifically
evaluate this area using a chronic pain questionnaire although
patients were asked about pain during their medical assessment.
The results of this analysis have benefited the design of
an extension to this current study, where the quality of life
measure has been replaced. More work needs to be undertaken to
understand function in relationship to these new PROMs and to
evaluate if change in function over time is reflected in the related
PROM. Further work can also commence on refinement of some
of the current tools such as the EK scale and IPAQ.
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